Skip to content
Hair Pipeline
enfr
← Back to the pipeline

Bempikibart (ADX-914)

Bempikibart (ADX-914) is in Phase 2 for alopecia areata, developed by Q32 Bio.

An anti-IL-7 receptor antibody that Q32 Bio bet the company on, with a sponsor-reported 35% mean SALT reduction at 36 weeks in an open-label cohort and a registrational programme planned for 2027.

Phase 2BiologicInjectableImmunomodulator

Monthly digest of verified phase changes. A confirmation link goes out first; unsubscribe is one click on every mail.

Developed by
Q32 Bio
Current phase
Phase 2

Tests whether it works, at what dose, in a few hundred people.

Mechanism
Immunomodulator

Retunes the immune system more broadly than a single pathway.

Indications
Alopecia areata
Also known as
ADX-914, ADX914
Last public activity
May 2026
Copy last reviewed
September 2026
Record confidence
High

A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.

How it is meant to work

A fully human antibody against the IL-7 receptor alpha chain, which blocks both IL-7 and TSLP signalling, two cytokines implicated in T-cell-driven disease. The company's word for what it hopes to achieve is remittive, a response that outlasts the dosing, and it says its early data may be suggestive of one.

Why it matters

In February 2025 Q32 Bio shut its other clinical programme to fund this one. Part B of SIGNAL-AA enrolled 33 adults with severe or very severe disease, 36% of them previously on a JAK inhibitor. At 36 weeks the company reported a mean SALT reduction of 35.3% among the 25 patients in its evaluable population, a SALT score of 20 or below in 40% of them, and in 30% of all 33 who started. No serious treatment-related adverse events; injection-site reactions in about a third. Part A had shown responses still improving at week 55, after dosing stopped. In September 2026 it reported 16 weeks of follow-up after dosing stopped in Part B: of the 18 patients who entered it, 44% had a SALT score of 20 or below at the end, and none of the 12 who had regrown hair by week 36 worsened by 20 SALT points or more, which is the company's definition of a maintained response. The company intends to start a registration-directed programme in the first half of 2027. Sponsor topline figures, no placebo arm in Part B.

Development history

  1. Phase 2

    First Phase 2 trial on record: NCT06018428 — A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

    ClinicalTrials.gov ↗

Registered trials

Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.

  • NCT06018428Phase 2Active, not recruiting

    A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

    Q32 Bio Inc. · n=75 · September 2023

Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.

Sources

Related programmes

Other programmes in the register with the same mechanism: Immunomodulator.

Cite this page

Hair Pipeline, "Bempikibart (ADX-914) — development record", hairpipeline.com/pipeline/bempikibart